Compare ASMB & SLP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ASMB | SLP |
|---|---|---|
| Founded | 2005 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 442.9M | 367.9M |
| IPO Year | 2010 | 1996 |
| Metric | ASMB | SLP |
|---|---|---|
| Price | $26.75 | $18.25 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 6 |
| Target Price | ★ $44.20 | $24.00 |
| AVG Volume (30 Days) | 245.6K | ★ 692.5K |
| Earning Date | 05-06-2026 | 04-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 91.78 | N/A |
| EPS | N/A | ★ 0.43 |
| Revenue | N/A | ★ $59,577,000.00 |
| Revenue This Year | N/A | $3.80 |
| Revenue Next Year | $638.39 | $5.90 |
| P/E Ratio | ★ N/A | $42.37 |
| Revenue Growth | N/A | ★ 10.52 |
| 52 Week Low | $16.90 | $11.09 |
| 52 Week High | $39.71 | $21.01 |
| Indicator | ASMB | SLP |
|---|---|---|
| Relative Strength Index (RSI) | 50.41 | 63.43 |
| Support Level | $26.18 | $17.74 |
| Resistance Level | $30.68 | $18.62 |
| Average True Range (ATR) | 1.46 | 0.15 |
| MACD | 0.01 | -0.12 |
| Stochastic Oscillator | 46.08 | 19.44 |
Assembly Biosciences Inc is a clinical-stage biotechnology company. The Company's pipeline includes multiple clinical-stage investigational therapies, including: (1) two long-acting helicase-primase inhibitors (HPI) for the treatment of recurrent genital herpes; (2) an orally bioavailable hepatitis delta virus entry inhibitor; and (3) a potent next-generation capsid assembly modulator designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. The Company's pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) for the treatment of transplant-related herpesviruses.
Simulations Plus Inc is engaged in the software industry. It develops and produces software for use in pharmaceutical research and education, and provides consulting and contract research services to the pharmaceutical industry. The company's operating segments include Software and services. The company offers software products for pharmaceutical research such as ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity). It generates maximum revenue from the software segment. Maximum revenue is earned from USA following EMEA and Asia Pacific.